Id |
Subject |
Object |
Predicate |
Lexical cue |
T612 |
0-6 |
RB |
denotes |
Indeed |
T613 |
6-7 |
-COMMA- |
denotes |
, |
T614 |
8-10 |
IN |
denotes |
in |
T615 |
11-12 |
DT |
denotes |
a |
T616 |
13-18 |
JJ |
denotes |
small |
T617 |
19-22 |
CC |
denotes |
but |
T618 |
23-35 |
JJ |
denotes |
contemporary |
T619 |
36-43 |
NN |
denotes |
example |
T620 |
44-51 |
IN |
denotes |
outside |
T621 |
52-54 |
IN |
denotes |
of |
T622 |
55-65 |
JJ |
denotes |
infectious |
T623 |
66-73 |
NN |
denotes |
disease |
T624 |
73-74 |
-COMMA- |
denotes |
, |
T625 |
75-78 |
DT |
denotes |
the |
T626 |
79-91 |
NNP |
denotes |
FDA‐approved |
T627 |
92-103 |
NN |
denotes |
combination |
T628 |
104-106 |
IN |
denotes |
in |
T629 |
107-121 |
NN |
denotes |
adenocarcinoma |
T630 |
122-129 |
NN |
denotes |
therapy |
T631 |
130-134 |
VBZ |
denotes |
uses |
T632 |
135-136 |
DT |
denotes |
a |
T633 |
137-145 |
NN |
denotes |
cocktail |
T634 |
146-148 |
IN |
denotes |
of |
T635 |
149-152 |
CD |
denotes |
two |
T636 |
153-157 |
NNS |
denotes |
mAbs |
T637 |
157-158 |
-COMMA- |
denotes |
, |
T638 |
159-169 |
NN |
denotes |
pertuzumab |
T639 |
170-173 |
CC |
denotes |
and |
T640 |
174-185 |
NN |
denotes |
trastuzumab |
T641 |
185-186 |
-COMMA- |
denotes |
, |
T642 |
187-194 |
IN |
denotes |
against |
T643 |
195-203 |
NN |
denotes |
Her2.123 |
R628 |
T631 |
T612 |
arg1Of |
uses,Indeed |
R629 |
T631 |
T613 |
arg1Of |
uses,"," |
R630 |
T631 |
T614 |
arg1Of |
uses,in |
R631 |
T619 |
T614 |
arg2Of |
example,in |
R632 |
T619 |
T615 |
arg1Of |
example,a |
R633 |
T619 |
T616 |
arg1Of |
example,small |
R634 |
T616 |
T617 |
arg1Of |
small,but |
R635 |
T618 |
T617 |
arg2Of |
contemporary,but |
R636 |
T619 |
T618 |
arg1Of |
example,contemporary |
R637 |
T619 |
T620 |
arg1Of |
example,outside |
R638 |
T620 |
T621 |
arg1Of |
outside,of |
R639 |
T623 |
T621 |
arg2Of |
disease,of |
R640 |
T623 |
T622 |
arg1Of |
disease,infectious |
R641 |
T631 |
T624 |
arg1Of |
uses,"," |
R642 |
T627 |
T625 |
arg1Of |
combination,the |
R643 |
T627 |
T626 |
arg1Of |
combination,FDA‐approved |
R644 |
T627 |
T628 |
arg1Of |
combination,in |
R645 |
T630 |
T628 |
arg2Of |
therapy,in |
R646 |
T630 |
T629 |
arg1Of |
therapy,adenocarcinoma |
R647 |
T627 |
T631 |
arg1Of |
combination,uses |
R648 |
T633 |
T631 |
arg2Of |
cocktail,uses |
R649 |
T633 |
T632 |
arg1Of |
cocktail,a |
R650 |
T633 |
T634 |
arg1Of |
cocktail,of |
R651 |
T636 |
T634 |
arg2Of |
mAbs,of |
R652 |
T636 |
T635 |
arg1Of |
mAbs,two |
R653 |
T633 |
T637 |
arg1Of |
cocktail,"," |
R654 |
T639 |
T637 |
arg2Of |
and,"," |
R655 |
T638 |
T639 |
arg1Of |
pertuzumab,and |
R656 |
T640 |
T639 |
arg2Of |
trastuzumab,and |
R657 |
T631 |
T641 |
arg1Of |
uses,"," |
R658 |
T631 |
T642 |
arg1Of |
uses,against |
R659 |
T643 |
T642 |
arg2Of |
Her2.123,against |